Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALPINE IMMUNE SCIENCES, INC.ALPN · Entity 90802 | 10% owner | February 11, 2022 | February 15, 2022 |
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director | June 05, 2026 | June 12, 2026 |
| Frazier Lifesciences Acquisition CorpFLAC · Entity 122080 | Director | December 08, 2020 | December 17, 2020 |
| Imago BioSciences, Inc.IMGO · Entity 15490 | Director | July 20, 2021 | July 20, 2021 |
| Iterum Therapeutics plcITRM · Entity 72802 | Director | July 01, 2020 | July 06, 2020 |
| MBX Biosciences, Inc.MBX · Entity 4247 | Director · 10% owner | June 04, 2026 | June 05, 2026 |
| Mirum Pharmaceuticals, Inc.MIRM · Entity 2416 | Director | June 15, 2026 | June 18, 2026 |
| Passage BIO, Inc.PASG · Entity 7829 | Director · 10% owner | March 03, 2020 | March 03, 2020 |
| Phathom Pharmaceuticals, Inc.PHAT · Entity 5177 | 10% owner | June 12, 2020 | June 16, 2020 |
| Sierra Oncology, Inc.SRRA · Entity 125698 | 10% owner | February 14, 2017 | February 24, 2017 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director | June 02, 2021 | June 03, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALPINE IMMUNE SCIENCES, INC.
Report date February 11, 2022 · Filed February 15, 2022
Jointly reported with Frazier Life Sciences VIII, L.P., FHM LIFE SCIENCES VIII, L.P., FHM LIFE SCIENCES VIII, L.L.C., Topper James N
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,484,115 |
Reported balance
After 2022-02-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-02-11 · Purchase · Acquired 112,665 · Balance 1,484,115 F1: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James N. Topper and Patrick J. Heron are the sole managing members of FHM LLC. Mr. Topper, Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James N. Topper and Patrick J. Heron are the sole managing members of FHM LLC. Mr. Topper, Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any.
Arcutis Biotherapeutics, Inc.
Report date June 05, 2026 · Filed June 12, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Frazier Life Sciences X, L.P. | 27,448 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 27,448 F1: Due to a scrivener's error on the Reporting Person's Form 4 filed on June 9, 2026, the number of shares of common stock indirectly held by the Reporting Person through Frazier Life Sciences X, L.P. reflected a discrepancy that inadvertently understated the Reporting Person's indirect beneficial ownership by 2,646 shares. The correct number of shares so indirectly held by the Reporting Person is reflected in this Form 4/A. F2: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: Due to a scrivener's error on the Reporting Person's Form 4 filed on June 9, 2026, the number of shares of common stock indirectly held by the Reporting Person through Frazier Life Sciences X, L.P. reflected a discrepancy that inadvertently understated the Reporting Person's indirect beneficial ownership by 2,646 shares. The correct number of shares so indirectly held by the Reporting Person is reflected in this Form 4/A.
F2: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
Frazier Lifesciences Acquisition Corp
Report date December 08, 2020 · Filed December 17, 2020 · Amendment
Jointly reported with Topper James N, Frazier Lifesciences Sponsor LLC, Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-12-08 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance Not disclosed F1: As described in the Issuer's Registration Statement on Form S-1 (File No. 333-250858) (the "Registration Statement") under the heading "Description of Securities," the Class B Ordinary Shares will automatically convert into Class A Ordinary Shares of the Issuer at the time of the Issuer's initial business combination and have no expiration date. The shares reported herein include up to 450,000 Class B Ordinary Shares that are subject to forfeiture if the underwriter of the Issuer's initial public offering does not exercise in full its option to purchase additional units, as described in the Registration Statement. F2: Frazier Lifesciences Sponsor LLC is the record holder of the shares reported herein. Frazier Life Sciences X, L.P. is the sole member of Frazier Lifesciences Sponsor LLC. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. Mr. Topper is the Chief Executive Officer and Chairman of the Board of Directors (the "Board") of the Issuer. F3: By virtue of Mr. Topper's representation on the Issuer's Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons may be deemed directors by deputization of the Issuer. As such, each of Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Mr. Topper and Mr. Heron may be deemed to have or share beneficial ownership of the common stock held directly by Frazier Lifesciences Sponsor LLC. Each such entity or person disclaims any such beneficial ownership of such securities except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the Issuer's Registration Statement on Form S-1 (File No. 333-250858) (the "Registration Statement") under the heading "Description of Securities," the Class B Ordinary Shares will automatically convert into Class A Ordinary Shares of the Issuer at the time of the Issuer's initial business combination and have no expiration date. The shares reported herein include up to 450,000 Class B Ordinary Shares that are subject to forfeiture if the underwriter of the Issuer's initial public offering does not exercise in full its option to purchase additional units, as described in the Registration Statement.
F2: Frazier Lifesciences Sponsor LLC is the record holder of the shares reported herein. Frazier Life Sciences X, L.P. is the sole member of Frazier Lifesciences Sponsor LLC. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. Mr. Topper is the Chief Executive Officer and Chairman of the Board of Directors (the "Board") of the Issuer.
F3: By virtue of Mr. Topper's representation on the Issuer's Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons may be deemed directors by deputization of the Issuer. As such, each of Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Mr. Topper and Mr. Heron may be deemed to have or share beneficial ownership of the common stock held directly by Frazier Lifesciences Sponsor LLC. Each such entity or person disclaims any such beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Imago BioSciences, Inc.
Report date July 20, 2021 · Filed July 20, 2021
Jointly reported with FHM VII, L.L.C., FHM VII, L.P., Frazier Healthcare VII, L.P., Frazier Healthcare VII-A, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 41,582 |
Reported balance
After 2021-07-20 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-07-20 · Purchase · Acquired 41,582 · Balance 41,582 F1: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 145,918 |
Reported balance
After 2021-07-20 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-07-20 · Purchase · Acquired 145,918 · Balance 145,918 F2: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 383,514 |
Reported balance
After 2021-07-20 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-07-20 · Conversion · Acquired 341,932 · Balance 383,514 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F1: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 594,583 |
Reported balance
After 2021-07-20 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-07-20 · Conversion · Acquired 211,069 · Balance 594,583 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F1: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 658,943 |
Reported balance
After 2021-07-20 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2021-07-20 · Conversion · Acquired 64,360 · Balance 658,943 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F1: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,345,808 |
Reported balance
After 2021-07-20 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2021-07-20 · Conversion · Acquired 1,199,890 · Balance 1,345,808 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F2: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,086,481 |
Reported balance
After 2021-07-20 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2021-07-20 · Conversion · Acquired 740,673 · Balance 2,086,481 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F2: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,312,331 |
Reported balance
After 2021-07-20 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2021-07-20 · Conversion · Acquired 225,850 · Balance 2,312,331 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F2: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-07-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-07-20 · Conversion · Disposed 341,932 · Balance 0 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F1: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-07-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-07-20 · Conversion · Disposed 1,199,890 · Balance 0 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F2: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-07-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-07-20 · Conversion · Disposed 211,069 · Balance 0 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F1: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-07-20 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-07-20 · Conversion · Disposed 740,673 · Balance 0 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F2: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-07-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-07-20 · Conversion · Disposed 64,360 · Balance 0 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F1: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-07-20 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2021-07-20 · Conversion · Disposed 225,850 · Balance 0 F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date. F2: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any.
F2: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any.
F3: Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date.
Iterum Therapeutics plc
Report date July 01, 2020 · Filed July 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 9,006 |
Reported balance
After 2020-07-01 transaction · row 1
1 source rowRow 1 · 2020-07-01 · Exercise / conversion · Acquired 2,852 · Balance 9,006 F1: Restricted stock units converted into ordinary shares on a one-for-one basis upon vesting of the units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-07-01 · Exercise / conversion · Disposed 2,852 · Balance 0 F1: Restricted stock units converted into ordinary shares on a one-for-one basis upon vesting of the units. F4: On June 13, 2019, the reporting person was granted an award of 2,852 restricted stock units, which vested on July 1, 2020. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Frazier Healthcare VII, L.P. | 1,197,161 |
Reported balance
Holding disclosure · report date 2020-07-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,197,161 F2: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The sole general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The reporting person is one of six members of FHM VII, L.L.C. The reporting person, FHM VII, L.P. and FHM VII, L.L.C. disclaims Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Frazier Healthcare VII-A, L.P. | 341,155 |
Reported balance
Holding disclosure · report date 2020-07-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 341,155 F3: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The sole general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The reporting person is one of six members of FHM VII, L.L.C. The reporting person, FHM VII, L.P. and FHM VII, L.L.C. disclaims Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units converted into ordinary shares on a one-for-one basis upon vesting of the units.
F2: These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The sole general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The reporting person is one of six members of FHM VII, L.L.C. The reporting person, FHM VII, L.P. and FHM VII, L.L.C. disclaims Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any.
F3: These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The sole general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The reporting person is one of six members of FHM VII, L.L.C. The reporting person, FHM VII, L.P. and FHM VII, L.L.C. disclaims Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any.
F4: On June 13, 2019, the reporting person was granted an award of 2,852 restricted stock units, which vested on July 1, 2020.
MBX Biosciences, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.91 · Expires 2036-06-04 | Direct | 12,500 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 12,500 · Balance 12,500 F1: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.
Mirum Pharmaceuticals, Inc.
Report date June 15, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $101.00 · Expires 2036-06-14 | Direct | 3,772 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 3,772 · Balance 3,772 F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,980 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 1,980 · Balance 1,980 F2: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
F2: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.
Passage BIO, Inc.
Report date March 03, 2020 · Filed March 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Frazier Life Sciences IX, L.P. | 5,009,219 |
Last balance in matching sequence
After 2020-03-03 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2020-03-03 · Conversion · Acquired 2,977,242 · Balance 2,977,242 F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2: These securities are held of record by Frazier Life Sciences IX, L.P. ("Frazier Life Sciences"), of which FHMLS IX, L.P. ("FHMLS L.P.") is the general partner. FHMLS IX, L.L.C. ("FHMLS LLC") is the general partner of FHMLS L.P. The reporting person and James N. Topper are the managing members of FHMLS LLC and may be deemed to have shared voting and dispositive power over the shares held by Frazier Life Sciences. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Row 2 · 2020-03-03 · Conversion · Acquired 1,049,175 · Balance 4,026,417 F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2: These securities are held of record by Frazier Life Sciences IX, L.P. ("Frazier Life Sciences"), of which FHMLS IX, L.P. ("FHMLS L.P.") is the general partner. FHMLS IX, L.L.C. ("FHMLS LLC") is the general partner of FHMLS L.P. The reporting person and James N. Topper are the managing members of FHMLS LLC and may be deemed to have shared voting and dispositive power over the shares held by Frazier Life Sciences. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Row 3 · 2020-03-03 · Conversion · Acquired 432,802 · Balance 4,459,219 F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2: These securities are held of record by Frazier Life Sciences IX, L.P. ("Frazier Life Sciences"), of which FHMLS IX, L.P. ("FHMLS L.P.") is the general partner. FHMLS IX, L.L.C. ("FHMLS LLC") is the general partner of FHMLS L.P. The reporting person and James N. Topper are the managing members of FHMLS LLC and may be deemed to have shared voting and dispositive power over the shares held by Frazier Life Sciences. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Row 4 · 2020-03-03 · Purchase · Acquired 550,000 · Balance 5,009,219 F2: These securities are held of record by Frazier Life Sciences IX, L.P. ("Frazier Life Sciences"), of which FHMLS IX, L.P. ("FHMLS L.P.") is the general partner. FHMLS IX, L.L.C. ("FHMLS LLC") is the general partner of FHMLS L.P. The reporting person and James N. Topper are the managing members of FHMLS LLC and may be deemed to have shared voting and dispositive power over the shares held by Frazier Life Sciences. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Frazier Life Sciences IX, L.P. | 0 |
Reported balance
After 2020-03-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-03-03 · Conversion · Disposed 2,977,242 · Balance 0 F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2: These securities are held of record by Frazier Life Sciences IX, L.P. ("Frazier Life Sciences"), of which FHMLS IX, L.P. ("FHMLS L.P.") is the general partner. FHMLS IX, L.L.C. ("FHMLS LLC") is the general partner of FHMLS L.P. The reporting person and James N. Topper are the managing members of FHMLS LLC and may be deemed to have shared voting and dispositive power over the shares held by Frazier Life Sciences. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
| Series A-2 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Frazier Life Sciences IX, L.P. | 0 |
Reported balance
After 2020-03-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-03-03 · Conversion · Disposed 1,049,175 · Balance 0 F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2: These securities are held of record by Frazier Life Sciences IX, L.P. ("Frazier Life Sciences"), of which FHMLS IX, L.P. ("FHMLS L.P.") is the general partner. FHMLS IX, L.L.C. ("FHMLS LLC") is the general partner of FHMLS L.P. The reporting person and James N. Topper are the managing members of FHMLS LLC and may be deemed to have shared voting and dispositive power over the shares held by Frazier Life Sciences. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Frazier Life Sciences IX, L.P. | 0 |
Reported balance
After 2020-03-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-03-03 · Conversion · Disposed 432,802 · Balance 0 F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020. F2: These securities are held of record by Frazier Life Sciences IX, L.P. ("Frazier Life Sciences"), of which FHMLS IX, L.P. ("FHMLS L.P.") is the general partner. FHMLS IX, L.L.C. ("FHMLS LLC") is the general partner of FHMLS L.P. The reporting person and James N. Topper are the managing members of FHMLS LLC and may be deemed to have shared voting and dispositive power over the shares held by Frazier Life Sciences. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020.
F2: These securities are held of record by Frazier Life Sciences IX, L.P. ("Frazier Life Sciences"), of which FHMLS IX, L.P. ("FHMLS L.P.") is the general partner. FHMLS IX, L.L.C. ("FHMLS LLC") is the general partner of FHMLS L.P. The reporting person and James N. Topper are the managing members of FHMLS LLC and may be deemed to have shared voting and dispositive power over the shares held by Frazier Life Sciences. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Phathom Pharmaceuticals, Inc.
Report date June 12, 2020 · Filed June 16, 2020
Jointly reported with Frazier Life Sciences IX, L.P., FHMLS IX, L.P., FHMLS IX, L.L.C., Topper James N
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,827,415 |
Reported balance
After 2020-06-12 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-06-12 · Other · Disposed 1,456,854 · Balance 5,827,415 F1: Represents a pro rata distribution in-kind by Frazier Life Sciences IX, L.P. ("FLS IX") to its limited partners for no consideration. F2: Represents shares held of record by FLS IX. The general partner of FLS IX is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, L.L.C. James Topper and Patrick Heron are the sole managing members of FHMLS IX, L.L.C. and share voting and investment power of the securities held by FLS IX. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1 |
Reported balance
Holding disclosure · report date 2020-06-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1 F3: Reflects shares of Common Stock received in the distribution in-kind described herein. F4: Represents shares held of record by FHMLS IX, L.L.C. James Topper and Patrick Heron are the sole managing members of FHMLS IX, L.L.C. and share voting and investment power of the securities held by FLS IX. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. These shares were previously held through FLS IX. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 12,596 |
Reported balance
Holding disclosure · report date 2020-06-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 12,596 F3: Reflects shares of Common Stock received in the distribution in-kind described herein. F5: Represents shares held directly by Dr. Topper. These shares were previously held through FLS IX. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,912 |
Reported balance
Holding disclosure · report date 2020-06-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 3,912 F3: Reflects shares of Common Stock received in the distribution in-kind described herein. F6: Represents shares held of record by Topper Group III LLC. Dr. Topper is a manager of Topper Group III LLC and has voting and investment power of the securities held by Topper Group III LLC. These shares were previously held through FLS IX. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 14,937 |
Reported balance
Holding disclosure · report date 2020-06-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 14,937 F3: Reflects shares of Common Stock received in the distribution in-kind described herein. F7: Represents shares held by The Heron Living Trust 11/30/2004. Mr. Heron is the co-trustee of The Heron Living Trust 11/30/2004 and has voting and investment power of the securities held by The Heron Living Trust 11/30/2004. These shares were previously held through FLS IX. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro rata distribution in-kind by Frazier Life Sciences IX, L.P. ("FLS IX") to its limited partners for no consideration.
F2: Represents shares held of record by FLS IX. The general partner of FLS IX is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, L.L.C. James Topper and Patrick Heron are the sole managing members of FHMLS IX, L.L.C. and share voting and investment power of the securities held by FLS IX. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
F3: Reflects shares of Common Stock received in the distribution in-kind described herein.
F4: Represents shares held of record by FHMLS IX, L.L.C. James Topper and Patrick Heron are the sole managing members of FHMLS IX, L.L.C. and share voting and investment power of the securities held by FLS IX. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. These shares were previously held through FLS IX.
F5: Represents shares held directly by Dr. Topper. These shares were previously held through FLS IX.
F6: Represents shares held of record by Topper Group III LLC. Dr. Topper is a manager of Topper Group III LLC and has voting and investment power of the securities held by Topper Group III LLC. These shares were previously held through FLS IX.
F7: Represents shares held by The Heron Living Trust 11/30/2004. Mr. Heron is the co-trustee of The Heron Living Trust 11/30/2004 and has voting and investment power of the securities held by The Heron Living Trust 11/30/2004. These shares were previously held through FLS IX.
Sierra Oncology, Inc.
Report date February 14, 2017 · Filed February 24, 2017
Jointly reported with Frazier Healthcare VI, L.P., FHM VI, L.P., FHM VI, L.L.C., Frazier Life Sciences VIII, L.P., FHM LIFE SCIENCES VIII, L.P., FHM LIFE SCIENCES VIII, L.L.C., FRAZIER ALAN D, Naini Nader J, Every Nathan R
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,186,195 |
Reported balance
Holding disclosure · report date 2017-02-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,186,195 F1: Represents shares held by Frazier Healthcare VI, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | Direct | 5,925,926 |
Reported balance
Holding disclosure · report date 2017-02-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,925,926 F2: Represents shares held by Frazier Life Sciences VIII, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares held by Frazier Healthcare VI, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
F2: Represents shares held by Frazier Life Sciences VIII, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
Vaxcyte, Inc.
Report date June 02, 2021 · Filed June 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.49 · Expires 2031-06-01 | Direct | 15,000 |
Reported balance
After 2021-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-02 · Grant · Disposed 15,000 · Balance 15,000 F1: The shares subject to the option will vest monthly and fully vest on the earlier of June 2, 2022 or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest monthly and fully vest on the earlier of June 2, 2022 or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.
Past disclosures · reporting ended (6)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ANAPTYSBIO, INC
Report date May 11, 2018 · Filed May 15, 2018
Jointly reported with Frazier Healthcare VII, L.P., Frazier Healthcare VII-A, L.P., FHM VII, L.P., FHM VII, L.L.C., FRAZIER ALAN D, Naini Nader J, Every Nathan R
Section 16 reporting ended · disclosed 2018-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 973,612 |
Reported balance
After 2018-05-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-05-11 · Other · Disposed 1,372,000 · Balance 973,612 F1: Effective May 11, 2018, Frazier Healthcare V, L.P., distributed in-kind, without consideration, a total of 1,372,000 shares of Common Stock of the Issuer to its general and limited partners. The remaining securities are held by Frazier Healthcare V, L.P. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective May 11, 2018, Frazier Healthcare V, L.P., distributed in-kind, without consideration, a total of 1,372,000 shares of Common Stock of the Issuer to its general and limited partners. The remaining securities are held by Frazier Healthcare V, L.P. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
Aptinyx Inc.
Report date June 25, 2018 · Filed June 26, 2018
Jointly reported with Frazier Life Sciences VIII, L.P., FHM LIFE SCIENCES VIII, L.P., FHM LIFE SCIENCES VIII, L.L.C.
Section 16 reporting ended · disclosed 2018-06-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,190,079 |
Last balance in matching sequence
After 2018-06-25 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2018-06-25 · Conversion · Acquired 1,047,450 · Balance 1,047,450 F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Row 2 · 2018-06-25 · Conversion · Acquired 1,197,076 · Balance 2,244,526 F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Row 3 · 2018-06-25 · Conversion · Acquired 795,553 · Balance 3,040,079 F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. Row 4 · 2018-06-25 · Purchase · Acquired 150,000 · Balance 3,190,079 F3: On June 25, 2018, FLS-VIII purchased 150,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering. F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. |
| Series A-1 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-06-25 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-06-25 · Conversion · Disposed 28,895,188 · Balance 0 F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. |
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-06-25 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-06-25 · Conversion · Disposed 33,022,786 · Balance 0 F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2018-06-25 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-06-25 · Conversion · Disposed 21,946,301 · Balance 0 F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or consideration. The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date.
F2: The shares are held directly by Frazier Life Sciences VIII, L.P. ("FLS-VIII") and this report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII L.P."), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein.
F3: On June 25, 2018, FLS-VIII purchased 150,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering.
Entasis Therapeutics Holdings Inc.
Report date January 09, 2020 · Filed January 13, 2020
Jointly reported with Frazier Life Sciences VIII, L.P., Topper James N, FHM LIFE SCIENCES VIII, L.P., FHM LIFE SCIENCES VIII, L.L.C.
Section 16 reporting ended · disclosed 2020-01-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,299,953 |
Reported balance
After 2020-01-09 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-01-09 · Sale · Disposed 50,000 · Balance 1,299,953 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1 to this Form 4 F2: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1 to this Form 4
F2: The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any.
HilleVax, Inc.
Report date September 17, 2025 · Filed September 17, 2025
Jointly reported with Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Topper James N
Section 16 reporting ended · disclosed 2025-09-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Frazier Life Sciences X, L.P. | 0 |
Reported balance
After 2025-09-17 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-09-17 · Other · Disposed 8,535,337 · Balance 0 F1: Reflects disposition of the Issuer's equity securities upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on September 17, 2025. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of the Issuer's Common Stock, par value $0.0001 per share ("Shares"), issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive (i) $1.95 in cash, without interest plus (ii) one non-transferable contractual contingent value right per Share. F2: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X,, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Patrick J. Heron | 0 |
Reported balance
After 2025-09-17 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2025-09-17 · Other · Disposed 17,199 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the $1.95 by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of the Issuer's equity securities upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on September 17, 2025. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of the Issuer's Common Stock, par value $0.0001 per share ("Shares"), issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive (i) $1.95 in cash, without interest plus (ii) one non-transferable contractual contingent value right per Share.
F2: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X,, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the $1.95 by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU.
Tarsus Pharmaceuticals, Inc.
Report date October 20, 2020 · Filed October 21, 2020
Jointly reported with Frazier Life Sciences IX, L.P., FHMLS IX, L.P., FHMLS IX, L.L.C., Topper James N
Section 16 reporting ended · disclosed 2020-10-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,917,157 |
Last balance in matching sequence
After 2020-10-20 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2020-10-20 · Conversion · Acquired 1,390,376 · Balance 1,390,376 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein. Row 2 · 2020-10-20 · Conversion · Acquired 214,281 · Balance 1,604,657 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein. Row 3 · 2020-10-20 · Purchase · Acquired 312,500 · Balance 1,917,157 F2: The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-20 · Conversion · Disposed 1,390,376 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-20 · Conversion · Disposed 214,281 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2: The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.
F2: The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein.
Tobira Therapeutics, Inc.
Report date November 01, 2016 · Filed November 03, 2016
Section 16 reporting ended · disclosed 2016-11-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2019-06-23 | Direct | 0 |
Reported balance
After 2016-11-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-11-01 · Disposition to issuer · Disposed 4,332 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.52 · Expires 2025-07-08 | Direct | 0 |
Reported balance
After 2016-11-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-11-01 · Disposition to issuer · Disposed 15,500 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.91 · Expires 2026-01-12 | Direct | 0 |
Reported balance
After 2016-11-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-11-01 · Disposition to issuer · Disposed 17,778 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time")
F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"),
F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor.
F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 18, 2026 00:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantDeferred Stock Units · Derivative | 1,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001365617-26-000004 · form4-06172026_080605.xml · derivative · entry 2 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,980 Underlying: Common Stock · 1,980 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. F2 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. F2 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. Read SEC document |
| June 15, 2026 Filed Jun 18, 2026 00:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 3,772 | $0.00 Strike: $101.00 | $0.00 |
DisclosureSEC source: 0001365617-26-000004 · form4-06172026_080605.xml · derivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,772 Underlying: Common Stock · 3,772 shares Expires 2036-06-14 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Read SEC document |
| June 05, 2026 Filed Jun 10, 2026 01:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 16,667 | $0.00 Strike: $21.23 | $0.00 |
DisclosureSEC source: 0001628280-26-042046 · wk-form4_1781054489.xml · derivative · entry 6 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires 2036-06-05 F6 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document |
| June 05, 2026 Filed Jun 10, 2026 01:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 5,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-042046 · wk-form4_1781054489.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,213 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on October 21, 2025, maintained by the Company. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 11:59 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | GrantStock option (right to buy) · Derivative | 12,500 | $0.00 Strike: $30.91 | $0.00 |
DisclosureSEC source: 0001193125-26-258435 · ownership.xml · derivative · entry 1 Heron Patrick J · CIK 0001365617 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2036-06-04 F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 21:14 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 131,425 | $68.48 | $8,999,984.00 |
DisclosureSEC source: 0001365617-26-000002 · form4-01272026_090122.xml · nonDerivative · entry 2 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 459,010 F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 21:14 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | OtherCommon Stock | 159,277 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001365617-26-000002 · form4-01272026_090122.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 327,585 F1 · kind: Frazier Life Sciences X, L.P. received these shares in connection with merger of Bluejay Therapeutics, Inc. into the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's Common Stock was $94.29 per share. F1 · price: Frazier Life Sciences X, L.P. received these shares in connection with merger of Bluejay Therapeutics, Inc. into the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's Common Stock was $94.29 per share. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 20:59 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | PurchaseCommon Stock | 666,666 | $18.00 | $11,999,988.00 |
DisclosureSEC source: 0001231919-25-000267 · form4-09302025_080948.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director · 10% owner FHMLS X, L.P. · CIK 0001790880 · 10% owner FHMLS X, L.L.C. · CIK 0001790811 · 10% owner Topper James N · CIK 0001341382 · 10% owner Frazier Life Sciences X, L.P. · CIK 0001790879 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 5,219,440 F1 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 17, 2025 Filed Sep 17, 2025 21:20 UTC | HilleVax, Inc. HLVX · Entity 75097 | OtherCommon Stock | 17,199 | $1.95 | $33,538.05 |
DisclosureSEC source: 0001790879-25-000007 · form4-09172025_090911.xml · nonDerivative · entry 2 Frazier Life Sciences X, L.P. · CIK 0001790879 · 10% owner FHMLS X, L.P. · CIK 0001790880 · 10% owner FHMLS X, L.L.C. · CIK 0001790811 · 10% owner Topper James N · CIK 0001341382 · 10% owner Heron Patrick J · CIK 0001365617 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Patrick J. Heron Disclosed balance after: 0 F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the $1.95 by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU. Read SEC document |
| September 17, 2025 Filed Sep 17, 2025 21:20 UTC | HilleVax, Inc. HLVX · Entity 75097 | OtherCommon Stock | 8,535,337 | $1.95 | $16,643,907.15 |
DisclosureSEC source: 0001790879-25-000007 · form4-09172025_090911.xml · nonDerivative · entry 1 Frazier Life Sciences X, L.P. · CIK 0001790879 · 10% owner FHMLS X, L.P. · CIK 0001790880 · 10% owner FHMLS X, L.L.C. · CIK 0001790811 · 10% owner Topper James N · CIK 0001341382 · 10% owner Heron Patrick J · CIK 0001365617 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 0 F1 · price: Reflects disposition of the Issuer's equity securities upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on September 17, 2025. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of the Issuer's Common Stock, par value $0.0001 per share ("Shares"), issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive (i) $1.95 in cash, without interest plus (ii) one non-transferable contractual contingent value right per Share. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X,, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:07 UTC | HilleVax, Inc. HLVX · Entity 75097 | GrantCommon Stock | 17,199 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-090020 · ownership.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,199 F1 · shares: The Restricted Stock Units ("RSUs") were granted on June 23, 2025 pursuant to the Registrant's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (i) the first anniversary of the date of grant or (ii) a Change in Control (as defined in the Registrant's 2022 Incentive Award Plan), in each case, subject to the non-employee director continuing in service on the Registrant's board of directors through such vesting date. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 21:45 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | PurchaseCommon Stock | 2,646 | $13.08 | $34,610.47 |
DisclosureSEC source: 0001415889-25-017576 · form4-06172025_090658.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 27,448 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.945 to $13.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:17 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 20,568 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0002065881-25-000027 · wk-form4_1750119461.xml · derivative · entry 6 Heron Patrick J · CIK 0001365617 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,568 Underlying: Common Stock · 20,568 shares Expires 2035-06-12 F6 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:17 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 7,609 | $0.00 | $0.00 |
DisclosureSEC source: 0002065881-25-000027 · wk-form4_1750119461.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,435 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on October 23, 2024, maintained by the Company. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 12:02 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | GrantStock option (right to buy) · Derivative | 16,000 | $0.00 Strike: $11.86 | $0.00 |
DisclosureSEC source: 0000950170-25-082699 · ownership.xml · derivative · entry 1 Heron Patrick J · CIK 0001365617 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 12:44 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | PurchaseCommon Stock | 378 | $13.41 | $5,069.28 |
DisclosureSEC source: 0001415889-25-015883 · form4-06062025_120633.xml · nonDerivative · entry 2 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 24,802 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.21 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 12:44 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | PurchaseCommon Stock | 1,890 | $13.32 | $25,177.45 |
DisclosureSEC source: 0001415889-25-015883 · form4-06062025_120633.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 24,424 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.26 to $13.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 23:39 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantDeferred Stock Units · Derivative | 3,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015305 · form4-06022025_110622.xml · derivative · entry 6 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,977 Underlying: Common Stock · 3,977 shares Expires not disclosed F6 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. F6 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. F6 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 23:39 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 6,268 | $0.00 Strike: $44.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015305 · form4-06022025_110622.xml · derivative · entry 5 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,268 Underlying: Common Stock · 6,268 shares Expires 2035-05-28 F5 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 23:39 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionRestricted Stock Units · Derivative | 5,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015305 · form4-06022025_110622.xml · derivative · entry 4 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,703 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (or its cash equivalent, at the discretion of the Issuer). F4 · derivative.exercise_date: The restricted stock unit vests on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. F4 · derivative.expiration_date: The restricted stock unit vests on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 23:39 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 5,703 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-015305 · form4-06022025_110622.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (or its cash equivalent, at the discretion of the Issuer). Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:04 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | PurchaseCommon Stock | 2,520 | $13.65 | $34,398.00 |
DisclosureSEC source: 0001415889-25-014415 · form4-05232025_080546.xml · nonDerivative · entry 2 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 22,534 F1 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:04 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | PurchaseCommon Stock | 2,520 | $13.66 | $34,423.20 |
DisclosureSEC source: 0001415889-25-014415 · form4-05232025_080546.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 20,014 F1 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:14 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | PurchaseCommon Stock | 2,520 | $13.62 | $34,316.86 |
DisclosureSEC source: 0001415889-25-013620 · form4-05192025_080553.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 17,494 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.49 to $13.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 14, 2025 Filed May 15, 2025 20:18 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | PurchaseCommon Stock | 6,300 | $13.76 | $86,691.15 |
DisclosureSEC source: 0001415889-25-013137 · form4-05152025_080550.xml · nonDerivative · entry 2 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 14,974 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.5643 to $13.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4. F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:18 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | PurchaseCommon Stock | 2,374 | $13.76 | $32,660.78 |
DisclosureSEC source: 0001415889-25-013137 · form4-05152025_080550.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 8,674 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.70 to $13.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 09, 2025 Filed May 13, 2025 20:11 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | PurchaseCommon Stock | 6,300 | $13.60 | $85,691.34 |
DisclosureSEC source: 0001415889-25-012768 · form4-05132025_080532.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 6,300 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.1504 to $13.9266, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 21:04 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 21 | $43.93 | $922.61 |
DisclosureSEC source: 0001415889-25-008439 · form4-03182025_090327.xml · nonDerivative · entry 2 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 168,672 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $43.925 to $43.945, inclusive. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:04 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 528 | $44.11 | $23,291.40 |
DisclosureSEC source: 0001415889-25-008439 · form4-03182025_090327.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 168,651 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $44.00 to $44.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 20:51 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 963 | $43.77 | $42,155.13 |
DisclosureSEC source: 0001415889-25-007828 · form4-03122025_080317.xml · nonDerivative · entry 3 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 168,123 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $43.405 to $44, inclusive. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 20:51 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 577 | $43.37 | $25,023.34 |
DisclosureSEC source: 0001415889-25-007828 · form4-03122025_080317.xml · nonDerivative · entry 2 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 167,160 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $43.20 to $43.50, inclusive. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 20:51 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 758 | $42.66 | $32,339.46 |
DisclosureSEC source: 0001415889-25-007828 · form4-03122025_080317.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 166,583 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $43.42 to $43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (3) and (4) to this Form 4. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 21:12 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 580 | $43.21 | $25,064.41 |
DisclosureSEC source: 0001415889-25-007540 · form4-03102025_090354.xml · nonDerivative · entry 2 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 165,825 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $42.79 to $43.42, inclusive. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:12 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 1,335 | $43.89 | $58,596.89 |
DisclosureSEC source: 0001415889-25-007540 · form4-03102025_090354.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 165,245 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $43.42 to $44.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 22:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 267 | $44.55 | $11,893.52 |
DisclosureSEC source: 0001415889-25-007260 · form4-03062025_100339.xml · nonDerivative · entry 3 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 163,910 F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 22:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 56 | $45.96 | $2,573.74 |
DisclosureSEC source: 0001415889-25-007260 · form4-03062025_100339.xml · nonDerivative · entry 2 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 163,643 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $45.935 to $45.99, inclusive. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 22:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 1,279 | $45.55 | $58,256.66 |
DisclosureSEC source: 0001415889-25-007260 · form4-03062025_100339.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 163,587 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $44.935 to $45.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 20:39 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 115 | $37.40 | $4,301.00 |
DisclosureSEC source: 0001415889-24-023777 · form4-09202024_080957.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 162,308 F1 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS X, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences X, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:09 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | ConversionSeries B Convertible Preferred Stock · Derivative | 28,297,265 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107530 · ownership.xml · derivative · entry 4 Heron Patrick J · CIK 0001365617 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,353,769 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F2 · ownership.nature: These securities are held of record by Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:09 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | ConversionSeries A Convertible Preferred Stock · Derivative | 18,922,852 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107530 · ownership.xml · derivative · entry 3 Heron Patrick J · CIK 0001365617 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,574,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F2 · ownership.nature: These securities are held of record by Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:09 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | PurchaseCommon Stock | 625,000 | $16.00 | $10,000,000.00 |
DisclosureSEC source: 0000950170-24-107530 · ownership.xml · nonDerivative · entry 2 Heron Patrick J · CIK 0001365617 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 4,552,774 F3 · shares: Reflects shares purchased in the Issuer's initial public offering. F2 · ownership.nature: These securities are held of record by Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 00:09 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | ConversionCommon Stock | 3,927,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107530 · ownership.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 3,927,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date. F2 · ownership.nature: These securities are held of record by Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:04 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | GrantStock Option (Right to Buy) · Derivative | 15,963 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000950170-24-106439 · ownership.xml · derivative · entry 1 Heron Patrick J · CIK 0001365617 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,963 Underlying: Common Stock · 15,963 shares Expires 2034-09-11 F1 · derivative.exercise_date: 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 21:04 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 230 | $41.58 | $9,563.01 |
DisclosureSEC source: 0001415889-24-023154 · form4-09102024_090910.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Frazier Life Sciences X, L.P. Disclosed balance after: 162,193 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.50 to $41.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS X, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences X, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:52 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 27,052 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001787306-24-000104 · wk-form4_1718743928.xml · derivative · entry 2 Heron Patrick J · CIK 0001365617 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,052 Underlying: Common Stock · 27,052 shares Expires 2034-06-14 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:52 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 10,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000104 · wk-form4_1718743928.xml · nonDerivative · entry 1 Heron Patrick J · CIK 0001365617 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,826 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 06, 2024 Filed Apr 30, 2025 11:00 UTC | HilleVax, Inc. HLVX · Entity 75097 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $13.75 | $0.00 |
DisclosureSEC source: 0000950170-25-060553 · ownership.xml · derivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's non-employee director compensation program. The option shall vest and/or become exercisable on the first to occur of (i) the first anniversary of the grant date or (ii) the next occurring annual meeting of our stockholders, in each case, subject to the non-employee director continuing in service on our board of directors through such vesting dates. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 22:22 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantRestricted Stock Units · Derivative | 5,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016066 · form4-06072024_100603.xml · derivative · entry 2 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,703 Underlying: Common Stock · 5,703 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 22:22 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 8,779 | $0.00 Strike: $26.30 | $0.00 |
DisclosureSEC source: 0001415889-24-016066 · form4-06072024_100603.xml · derivative · entry 1 Heron Patrick J · CIK 0001365617 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,779 Underlying: Common Stock · 8,779 shares Expires 2034-06-04 F1 · derivative.exercise_date: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2025 annual stockholder meeting. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 20:22 UTC | HilleVax, Inc. HLVX · Entity 75097 | PurchaseCommon Stock | 8,850 | $14.50 | $128,325.00 |
DisclosureSEC source: 0001415889-24-010490 · form4-04082024_080405.xml · nonDerivative · entry 1 Frazier Life Sciences X, L.P. · CIK 0001790879 · 10% owner FHMLS X, L.P. · CIK 0001790880 · 10% owner FHMLS X, L.L.C. · CIK 0001790811 · 10% owner Topper James N · CIK 0001341382 · 10% owner Heron Patrick J · CIK 0001365617 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,544,187 F1 · ownership.direct: The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X,, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.